Tailored Solutions for Breast Cancer Diagnostics & Therapeutics Development
Alfa Cytology offers integrated and customized solutions to support the full spectrum of breast cancer research, from early-stage diagnostics to therapeutic validation. With our advanced platforms, scientific expertise, and personalized project management, we accelerate the development of novel strategies for breast cancer detection, monitoring, and therapeutic.
Our Services
Diagnostic Assay Design
Development and optimization of molecular and cellular assays for early detection, subtype classification, and therapy monitoring.
Targeted Therapeutics Development
Preclinical development of targeted agents including small molecules, monoclonal antibodies, and antibody-drug conjugates (ADCs) specifically for breast cancer subtypes.
Key Advantages
| Fully Customized Workflows | Each project is strategically designed to address specific preclinical research needs across different breast cancer subtypes (e.g., HER2+, ER+, TNBC), with flexibility in sample type and experimental design. |
| Cross-Platform Integration | Integration of multi-omics technologies-such as genomics, transcriptomics, and proteomics-with 2D, 3D, and animal models enhances the depth and reliability of preclinical insights. |
| High Translational Relevance | By employing patient-derived samples and physiologically relevant preclinical models, our services help bridge discovery and downstream clinical research, laying a solid foundation for future translational work. |
| IND-Oriented Data Support | All studies are conducted under rigorous preclinical standards, generating well-documented, high-quality data to support IND-enabling packages and early-stage regulatory planning. |
Download our service brochure to explore how our tailored breast cancer solutions can empower your diagnostics and therapeutic development pipeline. To discuss a customized project or receive a quote, please contact us directly.
Therapeutic Development for Breast Cancer
